An advisory committee to the Food and Drug Administration recommended unanimously Thursday that the agency approve the first test - a brain scan - that can show the characteristic plaques of Alzheimer's disease in the brain of a living person. The approval was contingent on radiologists agreeing on what the scans say and doctors being trained in how to read the scans.
The F.D.A. usually follows advice from its advisory committees, and Alzheimer's experts anticipated that the scans would be approved. The additional requirement would not be a big hurdle, said Dr. Daniel M. Skovronsky, chief executive of the company, Avid Radiopharmaceuticals, that applied to market the scans.
Read more: F.D.A. Sees Promise in Alzheimer's Imaging Drug